Legal Representation
Attorney
Isaac M. Fine
USPTO Deadlines
Next Deadline
57 days remaining
Abandonment Notice E-Mailed - No Use Statement Filed
Due Date
March 19, 2026
Application History
17 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jan 19, 2026 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Jan 19, 2026 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Dec 12, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Dec 12, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Dec 12, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jun 17, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Apr 18, 2025 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
| Apr 18, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Apr 18, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Apr 18, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Apr 22, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Apr 22, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 16, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Mar 26, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Mar 26, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 25, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 25, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
PHARMACEUTICAL PREPARATIONS FOR ALLEVIATING SIDE EFFECTS OF CANCER TREATMENTS; PHARMACEUTICAL PREPARATIONS FOR ALLEVIATING SIDE EFFECTS OF CHEMOTHERAPY; PHARMACEUTICAL PREPARATIONS FOR ALLEVIATING SIDE EFFECTS OF RADIATION THERAPY; PHARMACEUTICAL PREPARATIONS FOR ALLEVIATING SIDE EFFECTS OF TARGETED CANCER TREATMENTS; PHARMACEUTICAL PREPARATIONS FOR ALLEVIATING SIDE EFFECTS OF TARGETED CANCER TREATMENTS, NAMELY, TYROSINE KINASE INHIBITORS; PHARMACEUTICAL PREPARATIONS FOR ALLEVIATING SIDE EFFECTS OF IMMUNOTHERAPY TREATMENTS; PHARMACEUTICAL PREPARATIONS FOR ALLEVIATING GASTROINTESTINAL DISTRESS, MUCOCITIS, NAUSEA, VOMITING AND DIARRHEA; PHARMACEUTICAL PREPARATIONS FOR STIMULATING APPETITE; PHARMACEUTICAL PREPARATIONS FOR PREVENTING WEIGHT LOSS; PHARMACEUTICAL PREPARATIONS FOR PROTECTING BONE MARROW AND THE PRODUCTION OF BONE MARROW; PHARMACEUTICAL PREPARATIONS FOR PROTECTING STEM CELLS AND STIMULATING THE PRODUCTION OF STEM CELLS; PHARMACEUTICAL PREPARATIONS FOR INCREASING RESILIENCY OF STEM CELLS, INCREASING THE NUMBER OF STEM CELLS, AND PREVENTING THE REDUCTION OF STEM CELL POPULATIONS; PHARMACEUTICAL PREPARATIONS FOR PROTECTING BLOOD CELLS, ALLEVIATING ANEMIA, NEUTROPENIA, AND THROMBOCYTOPENIA, AND ALLEVIATING LOW BLOOD COUNT; PHARMACEUTICAL PREPARATIONS FOR ALLEVIATING DOSE LIMITING SIDE EFFECTS OF CANCER TREATMENTS, CHEMOTHERAPY, RADIATION THERAPY, TARGETED CANCER TREATMENTS AND IMMUNOTHERAPY TREATMENTS; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF SIDE EFFECTS OF CANCER TREATMENTS; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF SIDE EFFECTS OF CHEMOTHERAPY; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF SIDE EFFECTS OF RADIATION THERAPY; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF SIDE EFFECTS OF TARGETED CANCER TREATMENTS; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF SIDE EFFECTS OF TARGETED CANCER TREATMENTS, NAMELY, TYROSINE KINASE INHIBITORS; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF SIDE EFFECTS OF IMMUNOTHERAPY TREATMENTS; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF GASTROINTESTINAL DISTRESS, MUCOCITIS, NAUSEA, VOMITING AND DIARRHEA; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF LOSS OF APPETITE; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF WEIGHT LOSS; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT AND PREVENTION OF BONE MARROW DAMAGE; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT AND PREVENTION OF STEM CELL DAMAGE AND REDUCTION OF STEM CELL POPULATIONS; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT AND PREVENTION OF BLOOD CELL DAMAGE, ANEMIA, NEUTROPENIA, THROMBOCYTOPENIA AND LOW BLOOD COUNT; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT AND PREVENTION OF DOSE LIMITING SIDE EFFECTS OF CANCER TREATMENTS, CHEMOTHERAPY, RADIATION THERAPY, TARGETED CANCER TREATMENTS AND IMMUNOTHERAPY TREATMENTS; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT AND PREVENTION OF SIDE EFFECTS OF CANCER TREATMENTS, CHEMOTHERAPY, RADIATION THERAPY, TARGETED CANCER TREATMENTS AND IMMUNOTHERAPY TREATMENTS, NAMELY, REDUCED FERTILITY; FERTILITY ENHANCEMENT PREPARATIONS; PHARMACEUTICAL PREPARATIONS FOR SUPPORTING STEM CELL HEALTH AND PRODUCTION; PHARMACEUTICAL PREPARATIONS FOR SUPPORTING STEM CELL HEALTH AND PRODUCTION, NAMELY FOR STIMULATING UTERINE, BONE MARROW AND GASTROINTESTINAL TRACK STEM CELL PRODUCTION; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF RADIATION EXPOSURE
Classification
International Classes
005